Viz.ai has announced a collaboration with BIOS Clinical Trials Coordinating Center (BIOS CTTC) at Johns Hopkins University (Baltimore, USA) to expedite patient enrolment for the National Institutes of Health (NIH)-funded BEACH study, which is assessing a novel treatment for intracerebral haemorrhage (ICH).
With this partnership, BEACH research teams will have access to Viz.ai’s clinical trial acceleration platform, Viz RECRUIT software, which has demonstrated a three-fold acceleration in clinical trial enrolment—as per findings from the ENRICH study.
Viz.ai’s cloud-based technology broadens the recruitment funnel in both size and diversity by identifying patients at trial-eligible hospitals, according to a press release from the company. Viz RECRUIT identifies trial-eligible patients by scanning patient images in real-time, allowing for around-the-clock automatic identification of potential study subjects with notifications sent to research teams.
“By incorporating Viz RECRUIT software into the BEACH trial, we are enabling more patients with ICH to get access to novel treatments like MW189,” said Daniel Hanley (Johns Hopkins University, Baltimore, USA), co-principal investigator (PI) of the BEACH trial. “Success for the development of novel treatments like this is dependent upon increased enrolment in clinical trials, which in turn opens the door for larger trials of MW189 in acute CNS [central nervous system] injury and age-related dementias.”
The BEACH trial is studying the safety and tolerability of MW189, a small molecule, developed by co-PI Linda Van Eldik (University of Kentucky, Lexington, USA). It selectively attenuates injury- and disease-induced proinflammatory cytokine overproduction in ICH patients. A key design element is the early identification and treatment of eligible and consented participants in the first day of presentation.
The release adds that there is currently no approved treatment for ICH—a condition that results in high rates of mortality and long-term disability.
For the BEACH study specifically, Viz RECRUIT will automatically identify patients with suspected ICH, with trial inclusion volumetric assessment criteria between 10mL and 60mL; and notify members of the research and BIOS CTCC teams of trial candidates via Viz.ai’s web- and phone-based app that facilitates image viewing, communication, and coordination.
“Clinical trial enrolment is often a bottleneck when it comes to developing novel therapies,” said Jayme Strauss, chief clinical officer at Viz.ai. “Viz RECRUIT software is designed to speed up clinical trial enrolment and promote diversity in clinical trials by identifying more eligible participants. Together, with Johns Hopkins, we have an exciting opportunity to increase access to the BEACH trial, and help to enhance neurologic recovery and outcomes for patients.”
